DNA topoisomerase inhibitors - Pipeline Insight, 2024

DNA topoisomerase inhibitors - Pipeline Insight, 2024

DelveInsight’s, “DNA topoisomerase inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in DNA topoisomerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

DNA topoisomerase inhibitors Understanding

DNA topoisomerase inhibitors: Overview

Topoisomerases are essential and ubiquitous enzymes that regulate DNA topology by making temporary single- (type I) or double-strand DNA breaks (type II) [1], [2]. The DNA double helix needs to be unwound for processes such as DNA replication or transcription to take place, giving rise to the accumulation of positive supercoils ahead of transcription bubbles and replication forks, and negative supercoils or pre-catenanes behind. Topoisomerases relax supercoiled DNA and decatenate DNA to allow DNA transcription and replication to take place and are essential for genome stability

Function - DNA topoisomerases are enzymes that catalyze the alteration of DNA topology with transiently induced DNA strand breakage, essential for DNA replication. Topoisomerases are validated cancer chemotherapy targets. Anticancer agents targeting Topoisomerase I and II have been in clinical use and proven to be highly effective, though with significant side effects. There are tremendous efforts to develop new generation of topoisomerase inhibitors.

DNA topoisomerase inhibitors - Topoisomerase inhibitors are chemical compounds that block the action of topoisomerases, which are broken into two broad subtypes: type I topoisomerases (TopI) and type II topoisomerases (TopII). Topoisomerase plays important roles in cellular reproduction and DNA organization, as they mediate the cleavage of single and double stranded DNA to relax supercoils, untangle catenanes, and condense chromosomes in eukaryotic cells. Topoisomerase inhibitors influence these essential cellular processes. Some topoisomerase inhibitors prevent topoisomerases from performing DNA strand breaks while others, deemed topoisomerase poisons, associate with topoisomerase-DNA complexes and prevent the re-ligation step of the topoisomerase mechanism. These topoisomerase-DNA-inhibitor complexes are cytotoxic agents, as the un-repaired single and double stranded DNA breaks that they cause can lead to apoptosis and cell death. Because of this ability to induce apoptosis, topoisomerase inhibitors have gained interest as therapeutics against infectious and cancerous cells.

DNA topoisomerase inhibitors Emerging Drugs Chapters

This segment of the DNA topoisomerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

DNA topoisomerase inhibitors Emerging Drugs

• DNV3837: Deinove

DNV3837 is a water soluble prodrug that is rapidly dephosphorylated after intravenous administration in humans to produce DNV3681, the active form of the drug. Its structure results from the combination of two active moieties: a fluoroquinolone that inhibits bacterial DNA gyrase to interfere with replication of the bacterial genome and an oxazolidinone that inhibits initiation of bacterial protein synthesis. The drug is in phase II of clinical development for the treatment of Clostridium difficile infections.

• CXD 201: Celleron Therapeutics

CXD 201, a proprietary topoisomerase inhibitor, is being developed by Celleron Therapeutics (spin-off of Oxford University) and Nuance Biotech for the treatment of patients with colorectal cancer.

Further product details are provided in the report……..

DNA topoisomerase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different DNA topoisomerase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on DNA topoisomerase inhibitors

There are approx. 20+ key companies which are developing the DNA topoisomerase inhibitors. The companies which have their DNA topoisomerase inhibitors drug candidates in the most advanced stage, i.e. phase II include, Deinove.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

DNA topoisomerase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

DNA topoisomerase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses DNA topoisomerase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA topoisomerase inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence DNA topoisomerase inhibitors R&D. The therapies under development are focused on novel approaches for DNA topoisomerase inhibitors.

DNA topoisomerase inhibitors Report Insights

• DNA topoisomerase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

DNA topoisomerase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing DNA topoisomerase inhibitors drugs?
• How many DNA topoisomerase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for DNA topoisomerase inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DNA topoisomerase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for DNA topoisomerase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Deinove
• Celleron Therapeutics
• BioNumerik Pharmaceuticals
• Shasqi
• Mundipharma
• Oasmia Pharmaceutical
• Gibson Oncology
• GlaxoSmithKline
• Fujifilm Pharmaceuticals USA
• Ascelia Pharma
• Nektar Therapeutics
• Luye Pharma
• Targeted Therapy Technologies
• Athenex
• Cao Pharmaceuticals
• Intezyne
• RedxPharma

Key Products

• DNV3837
• CXD 201
• Cositecan
• SQ 3370
• Etoposide toniribate
• Research programme: cancer therapeutics
• Indotecan
• Gepotidacin
• Topotecan liposomal
• Irinotecan oral
• Etirinotecan pegol
• Irinotecan hydrochloride liposomal
• Episcleral topotecan
• Encequidar/topotecan
• CZ 48
• IT 141